Skip to main content
. Author manuscript; available in PMC: 2013 Nov 22.
Published in final edited form as: Sci Transl Med. 2013 May 22;5(186):186ra65. doi: 10.1126/scitranslmed.3005370

Figure. 2. Patients with cross-reactive antibodies have the most severe and progressive disease.

Figure. 2

(A) 194 patients in the ESCAPE RA cohort were divided into three groups according to their autoantibody status (Anti-PAD negative, Anti-PAD4 only, or Anti-PAD3/PAD4). The mean total baseline SvdH score for each group was determined and revealed a significant association of PAD3/PAD4 cross-reactive antibodies with Sharp score (Crude). (B) Sharp scores were available on 150 patients at follow-up, with progression depicted as the proportion of patients with any increase in SvdH score from baseline (Crude). These associations were maintained after adjusting for age, gender, RA duration, shared epitope alleles, anti-CCP status, and log CRP levels (Adjusted).